IDH1/2 mutations in acute myeloid leukemia
- Author:
Ja Min BYUN
1
;
Seung-Joo YOO
;
Hyeong-Joon KIM
;
Jae-Sook AHN
;
Youngil KOH
;
Jun Ho JANG
;
Sung-Soo YOON
Author Information
- Publication Type:REVIEW ARTICLE
- From:Blood Research 2022;57(1):13-19
- CountryRepublic of Korea
- Language:English
- Abstract: The mutational and epigenetic landscape of acute myeloid leukemia (AML) has become increasingly well understood in recent years, informing on biological targets for precision medicine. Among the most notable findings was the recognition of mutational hot-spots in the isocitrate dehydrogenase (IDH) genes. In this review, we provide an overview on the IDH1/2 mutation landscape in Korean AML patients, and compare it with available public data. We also discuss the role of IDH1/2 mutations as biomarkers and drug targets.Taken together, occurrence of IDH1/2 mutations is becoming increasingly important in AML treatment, thus requiring thorough examination and follow-up throughout the clinical course of the disease.
